Compare Global X Cybersecurity (BUG) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Cybersecurity vs Merck & Co., Inc. — how do they compare? Global X Cybersecurity trades at $42.91, while Merck & Co., Inc. trades at $130.73 (market cap $323.00B). The key difference: Merck & Co., Inc. pays a 2.6% dividend while Global X Cybersecurity pays none. Which is the better fit depends on your goals.
| BUG | MRK | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $43.00 | $131.84 |
52-Week Low | $23.30 | $77.60 |
Market Cap | — | $323.00B |
Enterprise Value | — | $369.77B |
Dividend Yield | — | 2.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BUG, the Global X Cybersecurity ETF, trades at $41.68, up 2.36% today and near its 52-week high, with a strong bullish technical signal from moving averages. The ETF has gained significant momentum, rising 82.25% from its 52-week low, as cybersecurity spending forecasts exceed $300 billion in 2026. Recent news highlights sector resilience against AI threats, though key financial ratios like P/E and P/S are not provided in the available data.
The outlook for BUG is positive, driven by robust cybersecurity demand and AI-related security needs, but risks include premium valuations, concentrated US SMID-cap exposure, and potential sector volatility. Analyst sentiment remains bullish with reiterated buy ratings, yet investors should note overbought short-term signals and competitive pressures in the evolving tech landscape.
MRK trades at $130.73, up 1.68% today, with a bullish technical signal and strong institutional buying. The stock shows consistent earnings beats, with Q3 2026 EPS expected at $2.27, and maintains solid profitability with a 72.97% gross margin. Recent acquisition of Terns Pharmaceuticals for approximately $6.7 billion aims to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
Outlook is positive with a consensus price target of $139.90, offering ~7% upside, supported by 67.57% analyst buy ratings. Risks include rising debt-to-asset ratio to 36.06% in 2025 and patent expirations, but strong cash flow and dividend payments provide stability. The stock presents a growth opportunity with manageable headwinds for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Cybersecurity
BUG is a thematic ETF that invests in companies at the forefront of the global cybersecurity industry. It provides concentrated exposure to leaders in network security, endpoint protection, and cloud security, such as Fortinet, Akamai, and CrowdStrike.
Read more on BUG →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
